Does Rallies show 13F holders for CGEM?

Yes. Rallies tracks hedge fund and 13F ownership data for CGEM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CGEM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGEM. It does not provide personalized investment advice.

CGEM (Cullinan Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cullinan Therapeutics, Inc. Common Stock (CGEM) is a publicly traded Healthcare sector company. As of May 21, 2026, CGEM trades at $14.03 with a market cap of $913.88M and a P/E ratio of 0.00. CGEM moved +0.95% today. Year to date, CGEM is +43.44%; over the trailing twelve months it is +81.39%. Its 52-week range spans $5.68 to $17.98. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces CGEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CGEM stock?

Hedge funds tracked by Rallies that own CGEM include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cullinan Therapeutics, Inc. Common Stock.

CGEM Key Metrics

Key financial metrics for CGEM
Metric	Value
Price	$14.03
Market Cap	$913.88M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$17.98
52-Week Low	$5.68
Volume	65
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-219.88M
Gross Margin	0.00%

Top Hedge Funds Holding CGEM

Orbimed Advisors holds 243.01K shares of CGEM, changed -10.00% as of Mar 31, 2026.
Centerbook Partners holds 43.99K shares of CGEM, changed -85.27% as of Dec 31, 2024.

Latest CGEM News

Cullinan’s $393M Cash Runway, Zipalertinib NDA Accepted, CLN-978 Data in June — May 7, 2026
Cullinan Therapeutics Holds $439M, Schedules Q2 CLN-978 Data and Zipalertinib NDA — Mar 10, 2026
Cullinan Therapeutics Prepares Q2 2026 CLN-978 Data Readout with AML Fast Track — Feb 13, 2026

Recent CGEM Insider Trades

Michaelson Jennifer sold 7.80K (~$113.88K) on May 5, 2026.
Michaelson Jennifer sold 200 (~$3.12K) on May 5, 2026.
Michaelson Jennifer sold 8.00K (~$125.44K) on Mar 5, 2026.

CGEM Analyst Consensus

11 analysts cover CGEM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.

Common questions about CGEM

Who owns CGEM stock?: Hedge funds tracked by Rallies that own CGEM include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cullinan Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for CGEM?: Yes. Rallies tracks hedge fund and 13F ownership data for CGEM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CGEM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGEM. It does not provide personalized investment advice.